References
- HaroutiunianSDrennanDALipmanAGTopical NSAID therapy for musculoskeletal painPain Med201011453554920210866
- American College of Gastroenterology [webpage on the Internet]Understanding ulcers, NSAIDs and GI bleedingBethesda, MDAmerican College of Gastroenterology Available from: http://s3.gi.org/patients/pdfs/UnderstandGIBleednew.pdfAccessed April 30, 2014
- SinghGTriadafilopoulosGEpidemiology of NSAID induced gastrointestinal complicationsJ Rheumatol Suppl199956182410225536
- LanasAGarcía-RodríguezLAArroyoMTInvestigators of the Asociación Española de Gastroenterología (AEG)Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulantsAm J Gastroenterol2007102350751517338735
- LanzaFLChanFKQuigleyEMPractice Parameters Committee of the American College of GastroenterologyGuidelines for prevention of NSAID-related ulcer complicationsAm J Gastroenterol2009104372873819240698
- CryerBLSostekMBFortJGSvenssonOHwangCHochbergMCA fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trialsAnn Med201143859460522017620
- GoldsteinJLHochbergMCFortJGZhangYHwangCSostekMClinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs enteric-coated naproxen aloneAliment Pharmacol Ther201032340141320497139
- BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
- VIMOVO®Product MonographMississauga, ONAstraZeneca Canada Inc2011
- U.S. Food and Drug Administration [webpage on the Internet]Esomeprazole strontium delayed-release capsulesSilver Spring, MDU.S. Food and Drug Administration2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202342Orig1s000TOC.cfmAccessed April 30, 2014
- ParekhPJOldfieldEC4thJohnsonDATreatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium)Expert Opin Pharmacother20141591215122224749891
- DhillonSNaproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcersDrugs Aging201128323724821329403
- Wang-SmithLFortJZhangYSostekMPharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-c oated naproxen and non-enteric-coated esomeprazole magnesiumJ Clin Pharmacol201252567068021628602
- U.S. Food and Drug Administration [webpage in the Internet]. Guidance for IndustryBioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154838.pdfAccessed June 28, 2014
- U.S. Food and Drug Administration [webpage on the Internet]Orange Book: Approved drug products with therapeutic equivalence evaluationsSilver Spring, MDU.S. Food and Drug Administration2015 Available from: http://www.fda.gov/cder/ob/default.htmAccessed June 28, 2014
- MaQLuAYPharmacogenetics, pharmacogenomics, and individualized medicinePharmacol Rev201163243745921436344
- Ingelman-SundbergMPharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and futureTrends Pharmacol Sci200425419320015063083
- YangJCLinCJCYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infectionExpert Opin Drug Metab Toxicol201061294119968574
- BaeJWKimJHChoiCIEffect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjectsArch Pharm Res200932226927319280158